MDNA.TO ( Mkap C$ 36M) (Cash C$20 M) Positive P2 Daten in Q1 könnten für Zulassung reichen (Seite 7)
eröffnet am 15.09.17 20:18:35 von
neuester Beitrag 07.05.24 20:11:42 von
neuester Beitrag 07.05.24 20:11:42 von
Beiträge: 89
ID: 1.261.920
ID: 1.261.920
Aufrufe heute: 0
Gesamt: 9.109
Gesamt: 9.109
Aktive User: 0
ISIN: CA58490H1073 · WKN: A2PA4V · Symbol: MDNA
2,3000
CAD
-5,74 %
-0,1400 CAD
Letzter Kurs 28.05.24 Toronto
Neuigkeiten
| TitelBeiträge |
|---|
22.05.24 · globenewswire  |
13.05.24 · globenewswire |
30.04.24 · globenewswire |
26.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0450 | +14.021,62 | |
| 48,34 | +119,73 | |
| 38,25 | +25,78 | |
| 38,81 | +23,21 | |
| 6,4200 | +21,13 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3800 | -22,47 | |
| 2,3500 | -30,47 | |
| 1,7000 | -31,17 | |
| 2,6950 | -41,09 | |
| 0,5280 | -41,46 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 60.131.301 von BTRRR am 18.03.19 16:52:43Bin hier auf einen sehr vielversprechenden Artikel gestoßen:
https://www.bnnbloomberg.ca/novel-drug-offers-hope-for-brain…
https://www.bnnbloomberg.ca/novel-drug-offers-hope-for-brain…
Antwort auf Beitrag Nr.: 60.131.301 von BTRRR am 18.03.19 16:52:43ich weiß nur, dass das Management viele Anteile hält um im Q2 die Daten kommen sollen. Bei positiven Daten fliegt hier der Deckel, allerdings schwirrt die Aktie leider im Moment noch unter dem Radar vieler...
Weiss hier jemand mehr?
Antwort auf Beitrag Nr.: 59.919.617 von Maggi110 am 20.02.19 12:59:30
Sehe ich auch so 😀
Habe Info vom Link:
Canadian Insider
Grüsse aus der Schweiz
Zubi
Sehe ich auch so 😀
Habe Info vom Link:
Canadian Insider
Grüsse aus der Schweiz
Zubi
Antwort auf Beitrag Nr.: 59.919.191 von zubi1955 am 20.02.19 12:21:59Sagen wir mal Vergütung 
Trading Spotlight
Antwort auf Beitrag Nr.: 59.871.175 von Bullrich83 am 14.02.19 10:06:40
Neueste Insidertransaktionen
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Merchant, Rosemina
Ownership Type
irect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:200,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Merchant, Fahar
Ownership Typeirect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:300,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Panchal, Chandra
Ownership Typeirect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Williams, Elizabeth
Ownership Typeirect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:200,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Li, William
Ownership Typeirect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Strong, Andrew
Ownership Typeirect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Beraldo, Albert George
Ownership Typeirect Ownership
Securities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Grüsse aus der Schweiz
Zubi
Neueste Insidertransaktionen
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Merchant, Rosemina
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:200,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Merchant, Fahar
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:300,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Panchal, Chandra
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Williams, Elizabeth
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:200,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Li, William
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Strong, Andrew
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Feb 14, 2019 (filed on Feb 19, 2019)
Insider Name:Beraldo, Albert George
Ownership Type
irect OwnershipSecurities:Options
Nature of Transaction:50 - Grant of options
# or value acquired/disposed of:50,000
Price:$1.00
Grüsse aus der Schweiz
Zubi
Antwort auf Beitrag Nr.: 59.805.528 von BTRRR am 06.02.19 15:39:14Die Zwischenergebnisse beziehen sich auf eine niedrige Dosierung. Entscheiden ist, denke ich, folgende Aussage:
Following treatment with MDNA55 at the low dose, the IL4R positive group showed a remarkable increase in median overall survival ("mOS") of 15.2 months when compared to 8.5 months in the IL4R negative group. Survival rates at 6, 9, and 12 months were 100%, 67% and 55% versus 73%, 40%, and 30%, in the IL4R positive and negative groups, respectively.
Read more at https://stockhouse.com/news/press-releases/2019/02/07/medice…
D.h. ist statistisch ein sichtbarer Unterschied zur Kontrollgruppe erkennbar. Ich denke, das sind positive Aussichten.
Im zweiten Studienteil wird auf höhere Dosierung getestet. Hoffen, wir dass die Sicherheitsrisiken mitspielen...
Gruß
Following treatment with MDNA55 at the low dose, the IL4R positive group showed a remarkable increase in median overall survival ("mOS") of 15.2 months when compared to 8.5 months in the IL4R negative group. Survival rates at 6, 9, and 12 months were 100%, 67% and 55% versus 73%, 40%, and 30%, in the IL4R positive and negative groups, respectively.
Read more at https://stockhouse.com/news/press-releases/2019/02/07/medice…
D.h. ist statistisch ein sichtbarer Unterschied zur Kontrollgruppe erkennbar. Ich denke, das sind positive Aussichten.
Im zweiten Studienteil wird auf höhere Dosierung getestet. Hoffen, wir dass die Sicherheitsrisiken mitspielen...
Gruß
Das heisst kurz gesagt?
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
TORONTO , Feb. 6, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, today announced that new pre-clinical data on its IL-2 Superkine program, MDNA109, will be presented today demonstrating lack of immunogenicity while achieving potent anti-tumor activity particularly when combined with anti-PD1 and anti-CTLA-4 checkpoint inhibitors.
The new results on MDNA109 and its long acting variants will be delivered in a podium presentation today titled, "Putting Pedal to the Metal: Combining IL-2 Superkine (MDNA109) with Checkpoint Inhibitors" by Moutih Rafei, PhD, Associate Professor, Department of Pharmacology and Physiology, Université de Montreal at the 5th Annual Immuno-Oncology 360o Meeting in New York, NY .
"We are continuing to make good progress in selecting a lead clinical candidate based on MDNA109, the only engineered IL-2 Superkine designed to specifically target CD122 (IL-2Rβ) without CD25 dependency", said Moutih Rafei PhD, Head of Discovery at Medicenna. "Our rationally engineered long acting MDNA109 candidates potently and selectively stimulate cancer killing effector T cells with exceptional synergy when combined with either anti PD-1 or anti-CTLA-4 checkpoint inhibitors. Competing IL-2 therapies in development with reduced CD25 binding require much higher doses for activating effector T cells to achieve a therapeutic effect. In contrast, MDNA109 in vitro activates effector T cells at about 10-fold lower doses due to a 1000-fold increase in affinity for the CD122 receptor."
The presentation will highlight the following:
MDNA109 is an engineered IL-2 superkine exhibiting 1000-fold enhanced affinity toward the CD122 receptor and best in class potency toward cancer killing effector T cells
When tested in vivo, MDNA109 was not immunogenic and led to potent delay in the growth of pre-established B16F10 tumors compared to IL-2.
Likewise, significant delay in the growth of pre-established MC38 and CT-26 colon cancer was observed in syngeneic mice receiving MDNA109, whereas its co-administration with anti-PD1 checkpoint inhibitor eliminated tumors in 90% of MC38 tumor-bearing mice.
Furthermore, MDNA109 in combination with anti-CTLA-4 antibody, complete responses were observed in a majority of mice in the CT26 model. When cured animals were re-challenged on the counter-lateral flank with CT26 tumor cells, tumor growth was blocked at the secondary site clearly suggesting the generation of potent memory responses.
Additional results on long-acting MDNA109 variants with impaired CD25 binding demonstrated abrogation of regulatory T cell activation at therapeutic doses in order to mitigate peripheral side effects, which are dependent on CD25 binding.
"Our IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines stimulate tumor-killing immune cells or block the immunosuppressive tumor micro-environment while synergizing with other cancer immunotherapy platforms for potent, targeted treatment", said Fahar Merchant , PhD, President and CEO of Medicenna. "We are excited with the results to date for MDNA109 and look forward to report further advances in the development of our first of many superkines."
About MDNA109
Developed by scientists at Stanford University, MDNA109 is an engineered version of IL-2 that binds up to 1,000 times more effectively to IL-2Rβ (CD122), thus greatly increasing its ability to activate and proliferate the immune cells needed to fight cancer. MDNA109 is an IL-2 Superkine that preferentially drives the expansion and responses of effector T cells and Natural Killer (NK) cells over Treg cells. It is the only IL-2 in development with a distinct mechanism by virtue of its high affinity towards CD122 allowing it to effectively combat NK cell anergy (exhaustion) which occurs frequently after cancer immunotherapy.
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs). Our mission is to become the leader in the development and commercialization of ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases. MDNA55 is Medicenna's lead EC currently enrolling in a multi-centre Phase 2 clinical trial for the treatment of recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. MDNA55 has secured Orphan Drug Status from the United States Food and Drug Administration (FDA) and the European Medicines Agency as well as Fast Track Designation from the FDA for the treatment of rGBM. For more information, please visit www.medicenna.com.
TORONTO , Feb. 6, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, today announced that new pre-clinical data on its IL-2 Superkine program, MDNA109, will be presented today demonstrating lack of immunogenicity while achieving potent anti-tumor activity particularly when combined with anti-PD1 and anti-CTLA-4 checkpoint inhibitors.
The new results on MDNA109 and its long acting variants will be delivered in a podium presentation today titled, "Putting Pedal to the Metal: Combining IL-2 Superkine (MDNA109) with Checkpoint Inhibitors" by Moutih Rafei, PhD, Associate Professor, Department of Pharmacology and Physiology, Université de Montreal at the 5th Annual Immuno-Oncology 360o Meeting in New York, NY .
"We are continuing to make good progress in selecting a lead clinical candidate based on MDNA109, the only engineered IL-2 Superkine designed to specifically target CD122 (IL-2Rβ) without CD25 dependency", said Moutih Rafei PhD, Head of Discovery at Medicenna. "Our rationally engineered long acting MDNA109 candidates potently and selectively stimulate cancer killing effector T cells with exceptional synergy when combined with either anti PD-1 or anti-CTLA-4 checkpoint inhibitors. Competing IL-2 therapies in development with reduced CD25 binding require much higher doses for activating effector T cells to achieve a therapeutic effect. In contrast, MDNA109 in vitro activates effector T cells at about 10-fold lower doses due to a 1000-fold increase in affinity for the CD122 receptor."
The presentation will highlight the following:
MDNA109 is an engineered IL-2 superkine exhibiting 1000-fold enhanced affinity toward the CD122 receptor and best in class potency toward cancer killing effector T cells
When tested in vivo, MDNA109 was not immunogenic and led to potent delay in the growth of pre-established B16F10 tumors compared to IL-2.
Likewise, significant delay in the growth of pre-established MC38 and CT-26 colon cancer was observed in syngeneic mice receiving MDNA109, whereas its co-administration with anti-PD1 checkpoint inhibitor eliminated tumors in 90% of MC38 tumor-bearing mice.
Furthermore, MDNA109 in combination with anti-CTLA-4 antibody, complete responses were observed in a majority of mice in the CT26 model. When cured animals were re-challenged on the counter-lateral flank with CT26 tumor cells, tumor growth was blocked at the secondary site clearly suggesting the generation of potent memory responses.
Additional results on long-acting MDNA109 variants with impaired CD25 binding demonstrated abrogation of regulatory T cell activation at therapeutic doses in order to mitigate peripheral side effects, which are dependent on CD25 binding.
"Our IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines stimulate tumor-killing immune cells or block the immunosuppressive tumor micro-environment while synergizing with other cancer immunotherapy platforms for potent, targeted treatment", said Fahar Merchant , PhD, President and CEO of Medicenna. "We are excited with the results to date for MDNA109 and look forward to report further advances in the development of our first of many superkines."
About MDNA109
Developed by scientists at Stanford University, MDNA109 is an engineered version of IL-2 that binds up to 1,000 times more effectively to IL-2Rβ (CD122), thus greatly increasing its ability to activate and proliferate the immune cells needed to fight cancer. MDNA109 is an IL-2 Superkine that preferentially drives the expansion and responses of effector T cells and Natural Killer (NK) cells over Treg cells. It is the only IL-2 in development with a distinct mechanism by virtue of its high affinity towards CD122 allowing it to effectively combat NK cell anergy (exhaustion) which occurs frequently after cancer immunotherapy.
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs). Our mission is to become the leader in the development and commercialization of ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases. MDNA55 is Medicenna's lead EC currently enrolling in a multi-centre Phase 2 clinical trial for the treatment of recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. MDNA55 has secured Orphan Drug Status from the United States Food and Drug Administration (FDA) and the European Medicines Agency as well as Fast Track Designation from the FDA for the treatment of rGBM. For more information, please visit www.medicenna.com.
Bin hier jetzt auch dabei mit einer kleinen Position. Hatte die Aktie schon länger beobachtet, seitdem Biohero sie freundlicherweise vorgestellt hatte. Ich glaube, jetzt wird es hier langsam interessant.
Durchsuchen
